Fig. 3From: Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST a Patient with a large presacral/pelvic mass had progressed by volume at 12-week follow-up (+139 %) but not by RECIST (+17.2 %). b 3D rendering of the patient’s lesion at baseline better illustrates tumor size and shape. c Three months later, the tumor had undergone drastic anisotropic growth not detectable by RECISTBack to article page